Clinical trials
Phase 2 Small Cell Lung Carcinoma trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Terminated | 8 |
| Active, not recruiting | 5 |
| Recruiting | 3 |
| Unknown status | 3 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Samsung Medical Center | 6 |
| National Cancer Center, Korea | 5 |
| Amgen | 2 |
| Eli Lilly and Company | 2 |
| Se-Hoon Lee | 2 |
| AbbVie | 1 |
| AstraZeneca | 1 |
| Bayer | 1 |
| BioNTech SE | 1 |
| Boehringer Ingelheim | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Small Cell Lung Carcinoma | 35 |
| Lung Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Melanoma | 2 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
| Anus Neoplasms | 1 |
| Carcinoma, Small Cell | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Prostatic Neoplasms | 1 |
| Prostatic Neoplasms, Castration-Resistant | 1 |
Trials
Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.